Novabay Pharmaceuticals, Inc. Appoints Swan Sit as Class III Director
December 20, 2019 at 09:18 pm
Share
NovaBay Pharmaceuticals, Inc. appointed Ms. Swan Sit to fill the vacancy on the Board resulting from the increased Board size. Ms. Sit is an independent member of the Board and will be a Class III director to serve until the Company’s Annual Meeting of Stockholders in 2022, subject to her prior death, resignation or removal from office as provided by law.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
NOVABAY PHARMACEUTICALS, INC. 
